Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Stock

Equities

603392

CNE100004090

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-07-18 EDT 5-day change 1st Jan Change
74.22 CNY +1.13% Intraday chart for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. +12.42% -1.21%

Financials

Sales 2024 * 3.61B 496M 681M Sales 2025 * 6.16B 847M 1.16B Capitalization 94.13B 12.95B 17.78B
Net income 2024 * 2.32B 319M 438M Net income 2025 * 3.26B 449M 616M EV / Sales 2024 * 24.6 x
Net cash position 2024 * 5.27B 725M 995M Net cash position 2025 * 5.25B 723M 992M EV / Sales 2025 * 14.4 x
P/E ratio 2024 *
45.6 x
P/E ratio 2025 *
32.3 x
Employees 3,843
Yield 2024 *
0.11%
Yield 2025 *
0.18%
Free-Float 18.23%
More Fundamentals * Estimated data
Dynamic Chart
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Wantai Biological's Phase 3 Trials for Nine-Valent HPV Vaccine Yields Performed 'As Expected' MT
Wantai BioPharm's 2023 Profit Drops 74% on Revenue Drop; Shares Slump 3% MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wantai Biological Pharmacy Predicts Up to 75% Profit Decline in 2023 MT
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announces an Equity Buyback for CNY 400 million worth of its shares. CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. authorizes a Buyback Plan. CI
Wantai Biological Pharmacy's Profit Drops 36.8% in H1 MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wantai Biological Pharmacy’s Profit Slides 6.5% in Q1 as Revenue Falls 9% MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wantai BioPharm Enrolls First Subjects for Pneumonia Vaccine Trial MT
More news
1 day+1.13%
1 week+12.42%
Current month+12.66%
1 month+13.07%
3 months+11.24%
6 months+10.43%
Current year-1.21%
More quotes
1 week
65.08
Extreme 65.08
75.58
1 month
64.14
Extreme 64.14
75.58
Current year
47.62
Extreme 47.62
88.00
1 year
40.14
Extreme 40.14
88.00
3 years
40.14
Extreme 40.14
147.67
5 years
4.43
Extreme 4.4335
147.67
10 years
4.43
Extreme 4.4335
147.67
More quotes
Managers TitleAgeSince
Director of Finance/CFO 53 07-12-31
Chairman 60 96-12-31
Chief Administrative Officer 42 06-12-31
Members of the board TitleAgeSince
Chairman 60 96-12-31
66 -
Chairman 39 18-04-12
More insiders
Date Price Change Volume
24-07-19 74.22 +1.13% 4,292,573
24-07-18 73.39 -0.42% 4,448,858
24-07-17 73.7 +5.23% 8,726,742
24-07-16 70.04 +1.95% 5,397,486
24-07-15 68.7 +4.06% 6,540,406

End-of-day quote Shanghai S.E., July 18, 2024

More quotes
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is a China-based company mainly engaged in the production and sale of vaccine products. The Company operates two segments. Diagnostic segment produces and sells in vitro diagnostic reagents and instruments suitable for in vitro diagnostic reagent testing. Vaccine segment produces and sells vaccines. The in vitro diagnostic reagents mainly include enzyme-linked immunosorbent assay reagents, colloidal gold diagnostic reagents, biochemical diagnostic reagents, chemiluminescent diagnostic reagents, and others. The in vitro diagnostic instruments include fully automatic chemiluminescent immunoassay analyzers, dry fluorescent immunoassay analyzers, fully automatic nucleic acid purification, and others. The vaccines mainly include hepatitis E vaccine, bivalent human papillomavirus (HPV) vaccine and nasal spray COVID-19 vaccine.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
74.22 CNY
Average target price
69.85 CNY
Spread / Average Target
-5.89%
Consensus
  1. Stock Market
  2. Equities
  3. 603392 Stock